10-K: Owlet Inc. Details Capital Structure and Regulatory Landscape in 10-K Filing

Owlet Inc.'s 10-K filing provides a detailed overview of its capital structure, including common and preferred stock, and outlines the regulatory environment it operates within, including FDA authorizations and international compliance.

Summary

• Owlet Inc.'s 10-K filing details the company's capital structure, which includes 107,142,857 shares of Class A Common Stock and 10,741,071 shares of preferred stock.
• As of December 31, 2023, Owlet had one class of securities registered under Section 12 of the Securities Exchange Act of 1934: Common Stock.
• As of March 1, 2024, there were 37,000 shares of preferred stock issued and outstanding, with 27,750 designated as Series A Convertible Preferred Stock and 9,250 as Series B Convertible Preferred Stock.
• The document outlines the voting rights, liquidation preferences, and dividend rights of both common and preferred stockholders.
• The company's board of directors has the authority to issue preferred stock and determine its rights and preferences, which could impact the voting power and liquidation rights of common stockholders.
• Owlet received FDA marketing authorizations for its Dream Sock and BabySat products in 2023, marking a shift from a consumer technology company to a medical device company.
• The company is also working towards obtaining CE Marking in the European Union for its Dream Sock with medical device functionality.
• The filing discusses the various risks associated with the business, including a limited operating history, ongoing losses, and the need for additional capital.
• Owlet's products are subject to regulation by the FDA and other federal and state authorities in the U.S., as well as comparable authorities in foreign jurisdictions.
• The company relies on third-party manufacturers for its products and is subject to risks associated with these relationships.
• Owlet is also subject to various healthcare laws and regulations, including anti-kickback, fraud and abuse, and false claims laws.
• The company is also subject to data privacy and security laws, as well as anti-bribery and corruption laws.
• Owlet relies on a combination of patent, copyright, trademark, and trade secret laws to protect its intellectual property rights.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are positive developments such as FDA authorizations and cost reductions, the company's ongoing losses, need for additional capital, and material weaknesses in internal controls raise significant concerns. The overall sentiment is cautiously negative due to the financial challenges and risks outlined.

Positives

• Owlet received FDA marketing authorizations for its Dream Sock and BabySat products, which are significant milestones.
• The company has significantly reduced operating expenses, including marketing and advertising costs.
• Owlet is expanding into healthcare distribution and exploring insurance reimbursement for its products.
• The company has a large dataset of infant health and sleep data, which it believes will be invaluable in bridging the healthcare gap between hospital and home.
• Owlet has a strong brand with over 1 million social media followers and millions of website visitors each year.
• The company has a growing international presence with distribution partners in key global markets.
• Owlet has a robust manufacturer and supplier selection process including site audits, tooling design and setup quotes, open book pricing, quality specifications, and vendor guides.

Negatives

• Owlet has a limited operating history and has not been profitable to date.
• The company has experienced fluctuations in the growth of its business and anticipates this will continue.
• Owlet relies on a limited number of retailers for a substantial portion of its sales.
• The company relies on single manufacturers for the assembly of its Smart Sock, Dream Sock, and Owlet Cam products.
• Owlet has identified material weaknesses in its internal control over financial reporting.
• The company may need to raise additional capital in the future, which may not be available on acceptable terms.
• Owlet is subject to various risks associated with operating in international markets.
• The company is involved in ongoing litigation, including securities class action lawsuits.

Risks

• Owlet has a limited operating history and has not been profitable to date, which could affect its ability to continue as a going concern.
• The company faces the risk of product liability claims and may not have adequate insurance coverage.
• Operations in international markets expose Owlet to additional business, political, regulatory, operational, financial, and economic risks.
• The company's success depends on its reputation and brand, which could be harmed by negative publicity or product issues.
• Owlet may not be able to obtain key materials and components from sole or limited source suppliers.
• The company's business and operations may suffer in the event of IT system failures, cyberattacks, or deficiencies in its cybersecurity.
• Owlet is involved in ongoing litigation, including securities class action lawsuits, which could have a material adverse effect on its business.
• The company may need to raise additional capital in the future, which may not be available on terms acceptable to it.
• Owlet faces increasing competition from other companies, many of which have greater resources.
• The company's ability to use its net operating loss carryforwards may be limited.

Future Outlook

Owlet aims to become a leading brand in the digital parenting category by expanding its product suite, penetrating the medical market, and leveraging its data platform. The company is focused on achieving profitability and increasing customer lifetime value through new value-added services.

Management Comments

• The FDA marketing authorizations for both BabySat and Dream Sock marks a significant moment for the pediatric category, we believe solidifying the trust of consumers and healthcare professionals alike.
• We believe that this achievement is a testament to our unwavering dedication to enhancing accessibility and reinforcing confidence in our innovative solutions.
• We believe that the FDA marketing authorizations of our BabySat and Dream Sock products will accelerate the adoption of our products and position us as the preferred pediatric data monitoring platform that bridges the gap between the hospital and the home.
• We see an opportunity to grow our existing product suite with medical market penetration.
• We believe expanding our recognizable brand into new channels will help our offerings stand out in a highly fragmented market of pediatric monitoring product companies lacking a category leader.

Industry Context

Owlet operates in the pediatric digital health monitoring space, competing with established players like VTech and Nanit, as well as emerging innovators. The company's FDA authorizations and focus on data-driven insights position it as a potential leader in the market, which is seeing increased investment in infant care despite a slight decline in birth rates.

Comparison to Industry Standards

• Owlet's achievement of obtaining the first de novo authorization for at-home monitoring without a prescription sets a high regulatory bar for new entrants in the space, differentiating it from competitors.
• Unlike competitors like VTech, which primarily focuses on sound and video monitors, Owlet offers a combination of health monitoring and visual reassurance through its integrated sock and cam combo.
• While Masimo focuses on patient monitoring solutions for hospital and clinical settings, Owlet is targeting the home environment with its consumer-friendly wearable technology.
• Compared to Nanit, which offers a video monitor and integrated breathing wrap, Owlet's Dream Sock provides more detailed health data, including pulse rate and oxygen saturation levels.
• Hubble offers a variety of sound and video monitors, including options with wearable health monitoring capabilities, but Owlet's regulatory authorizations and comprehensive feature set provide a competitive edge.

Legal Proceedings

• In November 2021, two putative class action complaints were filed against Owlet in the U.S. District Court for the Central District of California, alleging violations of the Exchange Act related to the FDA's likely classification of the Owlet Smart Sock as a medical device requiring marketing authorization.
• The company intends to vigorously defend itself against these claims.

Stakeholder Impact

• Shareholders face the risk of dilution from future equity offerings and potential loss of investment if the company is unable to continue as a going concern.
• Employees may be affected by potential restructuring or cost-cutting measures.
• Customers may benefit from the company's focus on innovation and new product development, but may also be affected by product recalls or quality issues.
• Suppliers and creditors face the risk of non-payment if the company's financial condition deteriorates.

Next Steps

• Owlet will remain focused on commercializing its Dream Sock with Health Notifications and BabySat devices.
• The company will continue to develop its software and data platform to bring additional solutions into the home.
• Owlet will continue to expand into international and new geographic markets.
• The company will work with its notified body, BSI, on obtaining CE Marking in the European Union for its Dream Sock with medical device functionality.
• Owlet is focused on enlisting a wide variety of healthcare partners in 2024 to increase the accessibility and affordability of its products.
• The company will continue to innovate and pilot new value-added services to increase customer lifetime value.

Key Dates

Keywords

Owlet, Dream Sock, BabySat, FDA, medical device, preferred stock, common stock, intellectual property, regulatory, manufacturing, financial, capital, internal control, cybersecurity, risk factors